Physiomics lowers forecasts amid contract delays
3rd May 2024 11:21
(Sharecast News) - Therapeutics and medicine-focussed mathematical modelling and data science company Physiomics said in an update on Friday that, despite a robust pipeline of potential new business, it had experienced delays in signing several large contracts.
Read morePhysiomics secures 'substantial new contract' with existing pharma client
18th Mar 2024 09:43
(Sharecast News) - Mathematical modelling and data science company Physiomics has been awarded "a substantial new contract" by an existing large pharmaceutical client.
Read morePhysiomics revenue rises, losses narrow in first half
7th Mar 2024 12:50
(Sharecast News) - Physiomics reported revenue of £0.37m in its interim results on Thursday, up from the £0.34m it recorded a year earlier.
Read morePhysiomics secures contract with University of Sheffield
19th Feb 2024 10:16
(Sharecast News) - Data science firm Physiomics has been chosen by the University of Sheffield to support a grant-funded project focused on an insect model of cancer treatment.
Read morePhysiomics awarded further contract by Numab Therapeutics
5th Feb 2024 10:01
(Sharecast News) - Data science company Physiomics said on Monday that it had been awarded a further contract by an existing client.
Read morePhysiomics receives Innovate UK funding grant
10th Nov 2023 08:14
(Sharecast News) - Computational biology firm Physiomics said on Friday that it had been awarded a grant by Innovate UK and the Office for Life Sciences as part of the UK Government's Advancing Precision Medicine programme.
Read morePhysiomics inks contract extension with Numab Therapeutics
8th Aug 2023 15:49
(Sharecast News) - Mathematical modelling company Physiomics, which specialises in the development of oncology drugs and personalised medicine, confirmed a renewed contract with Numab Therapeutics on Tuesday.
Read morePhysiomics inks collaboration deal with ValiRx subsidiary
26th Apr 2023 13:17
(Sharecast News) - Physiomics announced on Wednesday that it has signed a collaborative services agreement with Inaphaea BioLabs - a wholly-owned subsidiary of ValiRx.
Read morePhysiomics to present work at US cancer research summit
14th Apr 2023 12:34
(Sharecast News) - Physiomics announced its participation in the American Association for Cancer Research (AACR) annual meeting on Friday, being held in Orlando on 14-19 April.
Read morePhysiomics wins further contract with Bicycle Therapeutics
10th Mar 2023 08:51
(Sharecast News) - Oncology consultancy Physiomics revealed on Friday that it had been awarded a further contract by existing client Bicycle Therapeutics.
Read morePhysiomics confident despite weaker first half
7th Mar 2023 17:05
(Sharecast News) - Oncology consultancy firm Physiomics reported revenue of £0.34m in its first half on Tuesday - a slight decrease from the £0.37m reported in the same period a year earlier.
Read morePhysiomics inks deal to work with Cancer Research UK
12th Oct 2022 12:42
(Sharecast News) - Modelling and simulation-focussed consultancy Physiomics that it has signed an agreement to work with Cancer Research UK, it announced on Wednesday.
Read morePhysiomics wins new contract with French pharma company
8th Apr 2022 09:13
(Sharecast News) - Oncology drug developer Physiomics has been awarded a contract by new client, the Servier Group, an international pharmaceutical company based in France.
Read morePhysiomics signs £0.3m of new agreements with Merck
13th Dec 2021 13:31
(Sharecast News) - Oncology consulting company Physiomics announced on Monday that it has signed new agreements with its existing client Merck with a total value of £0.3m.
Read morePhysiomics awarded further contracts with Merck
22nd Oct 2021 09:13
(Sharecast News) - Oncology drug development consultancy Physiomics said on Friday that it had been awarded two further contracts by existing client Merck.
Read more